Encompass Health Co. (NYSE:EHC) is Copeland Capital Management LLC’s 3rd Largest Position

Copeland Capital Management LLC lifted its holdings in Encompass Health Co. (NYSE:EHC) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,284,550 shares of the company’s stock after buying an additional 12,433 shares during the quarter. Encompass Health makes up about 2.2% of Copeland Capital Management LLC’s portfolio, making the stock its 3rd biggest position. Copeland Capital Management LLC owned 1.28% of Encompass Health worth $124,139,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of EHC. UMB Bank n.a. lifted its position in shares of Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares during the last quarter. V Square Quantitative Management LLC boosted its position in Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares during the period. Oakworth Capital Inc. bought a new position in Encompass Health in the 2nd quarter worth about $40,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Encompass Health by 58.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after acquiring an additional 198 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Encompass Health by 31.9% during the first quarter. GAMMA Investing LLC now owns 616 shares of the company’s stock valued at $51,000 after acquiring an additional 149 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the sale, the chief financial officer now owns 136,227 shares in the company, valued at $11,761,839.18. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on EHC. Truist Financial increased their price objective on Encompass Health from $104.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Barclays reduced their price target on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Leerink Partners assumed coverage on shares of Encompass Health in a report on Wednesday, July 10th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, KeyCorp began coverage on Encompass Health in a report on Friday, October 11th. They set an “overweight” rating and a $115.00 target price for the company. Eight research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $104.67.

Encompass Health Stock Down 1.5 %

EHC stock opened at $95.75 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08. Encompass Health Co. has a 52 week low of $57.55 and a 52 week high of $98.74. The stock has a market capitalization of $9.64 billion, a PE ratio of 25.88, a price-to-earnings-growth ratio of 1.43 and a beta of 0.88. The firm has a 50 day moving average of $93.03 and a 200 day moving average of $87.95.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.30 billion. During the same period in the previous year, the company earned $0.95 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Sell-side analysts forecast that Encompass Health Co. will post 4.18 earnings per share for the current year.

Encompass Health declared that its Board of Directors has initiated a share buyback plan on Wednesday, July 24th that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to purchase up to 5.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be given a $0.17 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a yield of 0.71%. Encompass Health’s dividend payout ratio is currently 18.38%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.